EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Serum Urate–Lowering Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia: A Randomized, Double‐Blind , Placebo‐Controlled , Dose‐Finding Trial

Robert Terkeltaub, Jisoo Lee, Jiyoung Min, Seonghye Shin, Kenneth G Saag iD

Arthritis & Rheumatology · 2023-07 · 75 (7) · 1275-1284

DOI: 10.1002/art.42447 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Arthritis & Rheumatology, online erschienen am 26.04.2023. Verfasst von Robert Terkeltaub und 4 weiteren Autor:innen. Beteiligte Einrichtung: VA San Diego Healthcare System, and University of California San Diego, San Diego. Hauptthemen laut MEDLINE: Gout, Hyperuricemia. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: LG Chem.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the safety and efficacy of the nonpurine xanthine oxidase inhibitor tigulixostat for lowering serum urate level in gout patients with hyperuricemia.

Methods

We conducted a multicenter, phase II, randomized, double‐blind, placebo‐controlled, parallel‐group, dose‐finding trial. After screening, gout patients with hyperuricemia were randomly assigned, after appropriate washout, to receive daily oral administration of 50 mg, 100 mg, or 200 mg of tigulixostat, or placebo for 12 weeks. Colchicine gout flare prophylaxis was administered to all patients. The primary end point was the proportion of patients with a serum urate level

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GoutHyperuricemiaHumansUric AcidGout SuppressantsTreatment OutcomeSymptom Flare UpDouble-Blind MethodFebuxostat

Substanzen

Uric AcidGout SuppressantsFebuxostat

Autor:innen und Institutionen

  • VA San Diego Healthcare System, and University of California San Diego, San Diego.
  • Life Sciences, LG Chem, Seoul, Republic of Korea.
  • Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham.

ORCID-Profile: Kenneth G Saag

Förderung

  • LG Chem

Zitieren

APA

Terkeltaub, R., Lee, J., Min, J., Shin, S., & Saag, K. G. (2023). Serum Urate–Lowering Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia: A Randomized, Double‐Blind , Placebo‐Controlled , Dose‐Finding Trial. Arthritis & Rheumatology, 75(7), 1275-1284. https://doi.org/10.1002/art.42447

Vancouver

Terkeltaub R, Lee J, Min J, Shin S, Saag KG. Serum Urate–Lowering Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia: A Randomized, Double‐Blind , Placebo‐Controlled , Dose‐Finding Trial. Arthritis & Rheumatology. 2023;75(7):1275-1284. doi:10.1002/art.42447

BibTeX
@article{Terkeltaub2023,
  author = {Terkeltaub, Robert and Lee, Jisoo and Min, Jiyoung and Shin, Seonghye and Saag, Kenneth G},
  title = {Serum Urate–Lowering Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia: A Randomized, Double‐Blind , Placebo‐Controlled , Dose‐Finding Trial},
  journal = {Arthritis & Rheumatology},
  year = {2023},
  volume = {75},
  number = {7},
  pages = {1275--1284},
  doi = {10.1002/art.42447}
}
Kostenlos starten →